These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30478887)

  • 1. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer.
    Atkinson CJ; Kawamata F; Liu C; Ham S; Győrffy B; Munn AL; Wei MQ; Möller A; Whitehall V; Wiegmans AP
    Mol Oncol; 2019 Apr; 13(4):725-737. PubMed ID: 30478887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer.
    Marzi L; Combes E; Vié N; Ayrolles-Torro A; Tosi D; Desigaud D; Perez-Gracia E; Larbouret C; Montagut C; Iglesias M; Jarlier M; Denis V; Linares LK; Lam EW; Martineau P; Del Rio M; Gongora C
    Br J Cancer; 2016 Nov; 115(10):1223-1233. PubMed ID: 27685445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
    Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
    Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of Krüppel-like factor 5 is associated with poor prognosis in patients with colorectal cancer.
    Takagi Y; Sakai N; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Suzuki D; Kagawa S; Mishima T; Nakadai E; Miyauchi H; Matsubara H; Ohtsuka M
    Cancer Sci; 2020 Jun; 111(6):2078-2092. PubMed ID: 32279400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
    Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
    J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
    Liu BS; Xia HW; Zhou S; Liu Q; Tang QL; Bi NX; Zhou JT; Gong QY; Nie YZ; Bi F
    Oncol Rep; 2018 Oct; 40(4):2171-2182. PubMed ID: 30106444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
    Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
    Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
    Chiu CF; Chang YW; Kuo KT; Shen YS; Liu CY; Yu YH; Cheng CC; Lee KY; Chen FC; Hsu MK; Kuo TC; Ma JT; Su JL
    Proc Natl Acad Sci U S A; 2016 May; 113(18):E2526-35. PubMed ID: 27091996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EpCAM Signaling Promotes Tumor Progression and Protein Stability of PD-L1 through the EGFR Pathway.
    Chen HN; Liang KH; Lai JK; Lan CH; Liao MY; Hung SH; Chuang YT; Chen KC; Tsuei WW; Wu HC
    Cancer Res; 2020 Nov; 80(22):5035-5050. PubMed ID: 32978170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
    Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
    Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
    Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
    Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An unconventional KITENIN/ErbB4-mediated downstream signal of EGF upregulates c-Jun and the invasiveness of colorectal cancer cells.
    Bae JA; Yoon S; Park SY; Lee JH; Hwang JE; Kim H; Seo YW; Cha YJ; Hong SP; Kim H; Chung IJ; Kim KK
    Clin Cancer Res; 2014 Aug; 20(15):4115-28. PubMed ID: 24893630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butein sensitizes HeLa cells to cisplatin through the AKT and ERK/p38 MAPK pathways by targeting FoxO3a.
    Zhang L; Yang X; Li X; Li C; Zhao L; Zhou Y; Hou H
    Int J Mol Med; 2015 Oct; 36(4):957-66. PubMed ID: 26310353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.
    Le Corre D; Ghazi A; Balogoun R; Pilati C; Aparicio T; Martin-Lannerée S; Marisa L; Djouadi F; Poindessous V; Crozet C; Emile JF; Mulot C; Le Malicot K; Boige V; Blons H; de Reynies A; Taieb J; Ghiringhelli F; Bennouna J; Launay JM; Laurent-Puig P; Mouillet-Richard S
    EBioMedicine; 2019 Aug; 46():94-104. PubMed ID: 31377347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
    Murphy M; Stordal B
    Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy against chemoresistant colorectal cancers: Inhibition of p38α modulates the effect of cisplatin in vitro and in vivo through the tumor suppressor FoxO3A.
    Germani A; Matrone A; Grossi V; Peserico A; Sanese P; Liuzzi M; Palermo R; Murzilli S; Campese AF; Ingravallo G; Canettieri G; Tezil T; Simone C
    Cancer Lett; 2014 Mar; 344(1):110-118. PubMed ID: 24215867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signal transduction pathways of the epidermal growth factor receptor in colorectal cancer and their inhibition by small molecules.
    Efferth T
    Curr Med Chem; 2012; 19(33):5735-44. PubMed ID: 23033949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.